Ariad Pharmaceuticals Inc fka ARIA

[JJM760]

"The huge gorilla in the room is that imatinib is going to become generic,” notes Charles Schiffer, a hematologist-oncologist at Wayne State University School of Medicine’s Karmanos Cancer Institute in Detroit. Novartis’s patent on the drug, which accounted for an estimated $4.7 billion in global sales this year, will expire in 2015 in the US, 2016 in the major EU countries and 2014 in Japan. “So, the issue is whether cost will or should be the driver, and many of us think it should and will be.”

That has been THE # 1 discussion on Ponatinib sales for quite some time now. Perhaps some pretty outstanding EPIC trial results will change some minds.